Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Mar 23;138(2):544–550.e4. doi: 10.1016/j.jaci.2016.01.018

Figure 4.

Figure 4

(A) Nucleofection of human B-cells with mutant IRF2BP2 construct (p.S551N) leads to reduced plasmablast formation 7 days after CPG stimulation versus wild type IRF2BP2 nucleofection, which reached statistical significance (p<0.02, denoted by *). Data shown reflects mean percentage of plasmablast formation after 7 days of culture, and represents five duplicate runs. (B) On the SVM hyperplane, the proband was predicted to fall in the non-polygenic region.